The symptoms of pancreatic cancer can be easily mistaken for other less serious conditions at first, meaning that it’s typically diagnosed when the disease is at an advanced stage when there are very limited treatment options. Professor Kevin Ryan in Glasgow is looking for molecular clues or ‘markers’ in samples of blood and urine that could be used to detect early pancreatic cancer. These markers will then be validated by comparing patient samples to healthy samples.

This research could identify new tests that could help doctors find pancreatic cancer earlier when more treatment options are available, ultimately helping more people to survive.  

The breakthroughs being made in Glasgow are only possible thanks to the generosity of Cancer Research UK supporters. With this support Cancer Research UK funds over 4,000 scientists, doctors and nurses across the UK.

More than a third of Cancer Research UK projects are funded by gifts left in Wills. Legacies breathe life into researchers’ work. They enable long-term research projects that lead to new treatments and continue to save lives for generations to come, leading us to a world where everybody can lead longer, better lives, free from the fear of cancer.

In the past 40 years, cancer survival has doubled in part thanks to Cancer Research UK’s pioneering research, funded by the generosity of their supporters. This cause is one that's close to our hearts here at Claphams Solicitors, which is why we've partnered with Cancer Research UK and our Will writing service has raised over £280,000 for the cause. 

Cancer Research UK wants to accelerate progress and see 3 in 4 people surviving their cancer by 2034. They cannot achieve this mission alone and rely on their dedicated scientists, doctors and nurses, and the generosity of their supporters across the UK.

1 in 2 people will get cancer in their lifetime*. All of us can support the research that will beat it.​

Pledge to leave a gift in your Will to Cancer Research UK today by visiting cruk.org/legacies.

*Ahmad AS et al, British Journal of Cancer, 2015​